Replies to post #3535 on TopDollar Investing

[TheFinalCD]

CYCC(Nasd) has a 17.4M Float and a 29.9M Market Cap=recipe for $ucce$$


with 27,000 shares short as of Dec. 15, according to Yahoo! Finance. Insiders hold only 7.6% of the company's shares, with another 40.2% owned by institutions. http://www.mffais.com/cycc



Jim Cramer's TheStreet.com says:

Cyclacel Pharma Skyrockets on Volume Surge

http://www.thestreet.com/_yahoo/story/10657798/1/cyclacel-pharma-skyrockets-on-volume-surge.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA


Cyclacel Pharma has a 17.4 million-share float with 27,000 shares short as of Dec. 15, according to Yahoo! Finance. Insiders hold only 7.6% of the company's shares, with another 40.2% owned by institutions.

[ThatStockGuy]

CBIS looks like it closed above the middle bollinger...should see a continued bullish movement

[TheFinalCD]

1/8/2010 BEFORE THE BELL -2: US HOT STOCKS TO WATCH Last update: 8:44:20 AM

By Kristina Peterson
Of DOW JONES NEWSWIRES
NEW YORK (Dow Jones)--

Cyclacel Pharmaceuticals Inc. (CYCC) Apollo Group's fiscal first-quarter profit rose a third as the education company continued to boost enrollment. But Apollo said the University of Phoenix received notice from the U.S. Department of Education listing concerns about the school's Title IV program policies. The company expects its liability from the findings will be about $1.5 million. In addition, Apollo expects to be required to post a $125 million letter of credit by Jan. 30 to comply with regulations governing the untimely return of unearned Title IV funds. Shares declined 6.6% to $59.66 premarket. Lawson Software's fiscal second-quarter profit fell 9% as margin expansion couldn't offset lower revenue. The business-software maker also said it planned to acquire privately held Healthvision Solutions Inc. for $160 million. For the first year after closing, Lawson expects Healthvision to add $60 million to $70 million in revenue and 6 cents to 7 cents in earnings before some costs associated with the transaction. Shares dropped 9.8% to $6.30 in premarket trading. Cyclacel Pharmaceuticals Inc. (CYCC) announced the publication of two journal articles that disclosed one of its drug candidates was effective in killing some lung-cancer cell lines. Shares rose 17% to $3.12 on the news.
http://investorshub.advfn.com/boards/board.aspx?board_id=9448